Offering upsized in response to investor demand
Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ Copenhagen: ONXEO), ("Onxeo" or the "Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced a capital raise for gross proceeds of approximately EUR 15 millionby means of a private placement via an accelerate book-build offering. Guggenheim Securities, LLC and Oddo BHF acted as Joint Bookrunners.
The operation, announced on June 19, 2017, was oversubscribed, bringing the amount raised from 12 M€ initially offered to 15 M€ at 4.25€ per share, representing a discount of 12.6% to the volume weighted average price of the Company's shares over the 3 last trading days before pricing.
US and European institutional investors specialized in healthcare and biotechnology have participated in the capital raise, significantly reinforcing the Company's shareholding structure.
"This placement strengthens both our cash position and our institutional shareholder base. With this support from leading healthcare institutions, we will be able to advance the development of our strategic assets", commented Judith Greciet, Chief Executive Officer of Onxeo. "The proceeds from this financing will help complete the development of Livatag® in hepatocellular carcinoma, explore the potential of Beleodaq® in combination, and support the ambitious development plan for AsiDNA™, our first-in-class DNA repair inhibitor."
Key characteristics of the offering
3,529,411 new shares, par value EUR 0.25 each, have been placed with qualified institutional investors in the United States and Europe. The order book was well covered based on strong demand from new and existing investors specialized in healthcare and biotechnology, including Financière de la Montagne, the main shareholder of the Company. 72% of the demand was allocated to US investors.
The new shares, representing approximately 7.5% of the issued share capital of the Company prior to the share capital increase, were issued today by a decision of the Company's Chief Executive Officer, using the delegations granted by the Boards of Directors on June 15 and June19 2017 pursuant to the eighteenth and twentieth resolutions of the extraordinary general meeting of the shareholders of the Company held on May 24, 2017 and in accordance with articles L. 225-136 of the French Commercial code (code de commerce) and L. 411-2(II) of the French monetary and financial code (code monétaire et financier
The capital raise was conducted by way of a private placement of new shares via an accelerated book-build offering announced on June 19, 2017.
The issue price of the new shares has been set at EUR 4.25 per share, representing a 12.6% discount to the volume weighted average price of the Company's shares on the regulated market of Euronext Paris over the 3 last trading days before pricing (i.e. from June 15, 2017 to June 19, 2017 inclusive), which was EUR 4.8645 pursuant to the twentieth resolution of the extraordinary general meeting of the shareholders of the Company held on May 24, 2017.
On an illustrative basis, a shareholder holding 1% of Onxeo's capital before the offering will now hold a stake of 0.93%.
Use of proceeds
The funds raised will be used to pursue the development of its orphan oncology programs, as well as for general corporate purposes.
Net proceeds will reinforce the cash position of the Company which amounted to EUR 21.7 million at 31 March 2017 and extend the Company's financial visibility into Q1 2019.
Admission to listing of the new shares
The new shares will carry dividend rights as from their issue date and be immediately fungible in all respects with the Company's existing shares. They are expected to be admitted to trading under the same code as the existing shares (ISIN FR0011341205) on June 22, 2017 on the regulated market of Euronext in Paris and as soon as possible on the regulated market of Nasdaq OMX in Copenhagen (Denmark).
The offering is not subject to a prospectus to be approved by the French financial markets authority (Autorité des marchés financiers
Standstill and lock-up provisions
Onxeo has entered into a lock-up agreement ending 90 calendar days after the date of the pricing of the offering, subject to certain customary exceptions. Executives and/or directors of the Company have also signed lock-up agreements with regard to the Company's shares that they hold, for the same period.
Attention is drawn to the risk factors related to the Company and its activities presented in section 18.104.22.168. of the 2016 reference document filed with the Autorité des marchés financiers on April 24, 2017 under number D.17-0423, which is available on the Autorité des marchés financiers website (www.amf-france.org) or on the Company's website (www.onxeo.com).
This announcement does not constitute a prospectus within the meaning of the Prospectus Directive or an offer to the public.
Onxeo is a biotechnology company developing innovative drugs for the treatment of orphan diseases in oncology, driven by high therapeutic demand in one of the fastest growing segments of the pharmaceutical industry.
Onxeo's objective is to become a major international player in the field of rare cancers. Its growth strategy is founded on the development of innovative, effective, and safe drugs based on breakthrough technologies that can make a real difference in the treatment of orphan oncology diseases and considerably improve the quality of life of patients affected by rare or resistant cancers.
Onxeo's comprehensive portfolio features a broad orphan oncology pipeline, with 3 major products in several on-going preclinical and clinical programs, alone or in combination for various cancer indications:
- Livatag® (Doxorubicin Transdrug™): Currently evaluated in the treatment of Hepatocellular carcinoma (HCC, also called primary liver cancer) in a phase III trial, ReLive. ReLive is a randomized, international trial designed to demonstrate the efficacy and the safety of Livatag® compared to the best available treatment chosen by the physician in 390 patients with advanced HCC after failure or intolerance to sorafenib.
- Beleodaq® (belinostat): FDA conditional approved in the US in 2014 under the agency's accelerated approval program as a second-line treatment for patients with peripheral T-cell lymphoma (PTCL) and currently marketed by Onxeo's partner in the US, Spectrum Pharmaceuticals; belinostat in combination with other cancer agents is currently in development in first-line treatment for patients with PTCL (BelCHOP) and in solid tumors.
- AsiDNATM: The first-in-class siDNA (signal-interfering DNA) which has successfully undergone a proof-of-concept Phase I trial with a local administration in metastatic melanoma. The Company is currently pursuing preclinical program to demonstrate AsiDNA activity with a systemic administration
The Company is headquartered in Paris, France with offices in Copenhagen and in New York, and has approximately 60 employees. Onxeo is listed on Euronext in Paris, France and Nasdaq Copenhagen, Denmark (Ticker: ONXEO, ISIN Code: FR0010095596).
Learn more by visiting www.onxeo.com
In France, the offer and sale of Onxeo SA shares described above will take place solely through a private placement, in accordance with Article L. 411-2 of the French Code monétaire et financier and applicable regulations. The offer and sale do not constitute a public offering in France, as defined in Article L. 411-1 of the French Code monétaire et financier and no prospectus needs to be filed with, or approved by, the Autorité des marchés financiers
With respect to Member States of the European Economic Area that have transposed European Directive 2003/71/EC of the European Parliament and European Council (as amended in particular by Directive 2010/73/EU to the extent that the said Directive has been transposed into each Member State of the European Economic Area) (the "Prospectus Directive"), no action has been taken or will be taken to permit a public offering of the securities referred to in this press release requiring the publication of a prospectus in any Member State. Therefore, such securities may not be and shall not be offered in any Member State other than in accordance with the exemptions of Article 3(2) of the Prospective Directive to the extent they have been transposed by the relevant Member State or, otherwise, in cases not requiring the publication of a prospectus under Article 3(2) of the Prospective Directive and/or the applicable regulations in such Member State.
This press release and the information it contains are being distributed to and are only intended for persons who are (i) outside the United Kingdom, (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), (iii) high net worth entities and other such persons falling within Article 49(2)(a) to (d) of the Order ("high net worth companies", "unincorporated associations", etc.) or (iv) other persons to whom an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the Financial Services and Market Act 2000) may otherwise lawfully be communicated or caused to be communicated (all such persons in (i), (ii), (iii) and (iv) together being referred to as "Relevant Persons"). Any invitation, offer or agreement to subscribe, purchase or otherwise acquire securities to which this press release relates will only be engaged with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this press release or any of its contents.
This press release and the information it contains does not, and will not, constitute an offer to subscribe for or sell, nor the solicitation of an offer to subscribe for or buy, securities of Onxeo SA in the United States of America or any other jurisdiction where restrictions may apply. Securities may not be offered or sold in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), it being specified that the securities of Onxeo SA have not been and will not be registered within the U.S. Securities Act. Onxeo SA does not intend to register securities or conduct a public offering in the United States of America.
In accordance with Article 211-3 of the General Regulation of the AMF, it is recalled that:
- the offer does not require a prospectus to be submitted for approval to the AMF.
- persons or entities referred to in Point 2°, Section II of Article L. 411-2 of the Monetary and Financial Code may take part in the offer solely for their own account, as provided in Articles D. 411-1, D. 411-2, D. 734-1, D. 744-1, D. 754-1 and D. 764-1 of the Monetary and Financial Code.
- the financial instruments thus acquired cannot be distributed directly or indirectly to the public otherwise than in accordance with Articles L. 411-1, L. 411-2, L. 412-1 and L. 621-8 to L. 621-8-3 of the Monetary and Financial Code.
The distribution of this press release may be subject to legal or regulatory restrictions in certain jurisdictions. Any person who comes into possession of this press release must inform him or herself of and comply with any such restrictions.
Any decision to subscribe for or purchase the shares or other securities of Onxeo SA must be made solely based on information publicly available about Onxeo SA. Such information is not the responsibility of Guggenheim Securities, LLC and Oddo BHF Corporate Markets and has not been independently verified by Guggenheim Securities, LLC and Oddo BHF Corporate Markets.
Forward looking statements
This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the section 22.214.171.124 "Risk Factors" ("Facteurs de Risque") of the 2016 reference document filed with the Autorité des marchés financiers on April 24, 2017 under number D.17-0423, which is available on the Autorité des marchés financiers website (www.amf-france.org) or on the Company's website (www.onxeo.com
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA AND JAPAN.
+33 1 45 58 76 00
+33 6 64 18 99 59 +33 6 38 16 26 41
Investor Relations Strategic Communications
Dušan Orešanský Emmanuel Huynh
+33 1 44 71 94 92
Investor Relations US
+1 212 915 2578